About: Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study
Creator	Ba, Albertson-Junkans, Ladia Dublin, Sascha Floyd, James Fuller, Sharon Green, Beverly Greenwood-Hickman, Mikael Harrington, Laura Psaty, Bruce Shortreed, Susan Walker, Rod Washington, Kaiser
source	MedRxiv; Medline; PMC
abstract	There are plausible mechanisms by which angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase the risk of COVID-19 infection or affect disease severity. To examine the association between these medications and COVID-19 infection or hospitalization, we conducted a retrospective cohort study within a US integrated healthcare system. Among people aged ≥18 years enrolled in the health plan for at least 4 months as of 2/29/2020, current ACEI and ARB use was identified from pharmacy data, and the estimated daily dose was calculated and standardized across medications. COVID-19 infections were identified through 6/14/2020 from laboratory and hospitalization data. We used logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals. Among 322,044 individuals, 720 developed COVID-19 infection. Among people using ACEI/ARBs, 183/56,105 developed COVID-19 (3.3 per 1000 individuals) compared with 537/265,939 without ACEI/ARB use (2.0 per 1000), yielding an adjusted OR of 0.94 (95% CI 0.75-1.16). For use of < 1 defined daily dose vs. nonuse, the adjusted OR for infection was 0.89 (95% CI 0.62-1.26); for 1 to < 2 defined daily doses, 0.97 (95% CI 0.71-1.31); and for ≥2 defined daily doses, 0.94 (95% CI 0.72-1.23). The OR was similar for ACEIs and ARBs and in subgroups by age and sex. 29% of people with COVID-19 infection were hospitalized; the adjusted OR for hospitalization in relation to ACEI/ARB use was 0.92 (95% CI 0.54-1.57), and there was no association with dose. These findings support current recommendations that individuals on these medications continue their use.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.1101/2020.07.06.20120386
bibo:pmid	32676610
has license	cc-by-nc-nd
sha1sum (hex)	3e076d86865a8bf6a46ed6e5be5d0bea2a54e802
schema:url	https://doi.org/10.1101/2020.07.06.20120386
resource representing a document's title	Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study
has PubMed Central identifier	PMC7359535
has PubMed identifier	32676610
schema:publication	medRxiv
resource representing a document's body	covid:3e076d86865a8bf6a46ed6e5be5d0bea2a54e802#body_text
is schema:about of	named entity 'doses' named entity 'pharmacy' named entity 'COVID-19' named entity 'infection' named entity '95% CI' named entity 'relation' named entity 'infection' named entity 'inhibitors' named entity 'DOSES' named entity 'ACROSS' named entity 'SEX' named entity 'IDENTIFIED' named entity '0.75' named entity 'ESTIMATED' named entity '282' named entity '0.92' named entity 'RISK OF' named entity 'HEALTHCARE SYSTEM' named entity 'hospitalization' named entity 'laboratory' named entity 'infection' named entity '95% CI' named entity 'infection' named entity 'confidence intervals' named entity '95% CI' named entity 'health plan' named entity '95% CI' named entity 'ACEI' named entity 'healthcare system' named entity '2.0' named entity 'COVID-19 infection' named entity 'ARBs' named entity 'angiotensin-converting enzyme inhibitors' named entity 'retrospective cohort study' named entity 'ACEIs' named entity '95% CI' named entity '95% CI' named entity 'Renin-angiotensin-aldosterone' named entity 'cohort study' named entity 'identified' named entity 'COVID' named entity 'ARBs' named entity 'RAAS' named entity 'Logistic regression' named entity 'infection' named entity 'COVID-19 infection' named entity 'follow-up' named entity 'outpatient' named entity 'COVID-19 testing' named entity 'adjusted odds ratio' named entity 'prednisone' named entity 'CC-BY-NC-ND 4.0' named entity 'non-Hispanic white' named entity 'ACEI' named entity 'medRxiv' named entity 'Demographic characteristics' named entity 'adverse effect' named entity '95% CI' named entity 'Vienna' named entity 'infection' named entity 'Kaiser Permanente Washington Health Research Institute' named entity 'calcium channel blockers' named entity 'comorbidity' named entity 'coronavirus disease 2019' named entity 'infection' named entity 'SARS-CoV-2' named entity 'July 7' named entity 'renal disease' named entity 'residual confounding' named entity 'asthma'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software